Randomized Placebo Controlled Trial of IVIg in Glycine Receptor Antibody Positive Stiff-person Syndrome
Status:
Withdrawn
Trial end date:
2019-04-26
Target enrollment:
Participant gender:
Summary
This is a randomized double-blind controlled trial of intravenous immunoglobulin (IVIg) for
glycine receptor antibody positive (GlyRα1) antibody Stiff Person Syndrome (SPS) spectrum
disorders. Adult patients will be enrolled over the course of 36 months. Study duration per
patient will be 11 weeks. Total study duration will be 39 months. All treatment and study
visits will occur at Mayo Clinic in Rochester, MN.